Scientific
programme

The scientific programme has been developed independently and is free from any commercial influence.

This event is organised in accordance with the principles of CME accreditation and applicable ethical and compliance standards.

Download PDF
12:00-12:45Registration & Lunch
12:45-13:00Welcome and Opening Remarks
12:45-12:50Welcome – Michał Nowicki & Eleni Frangou
12:50-13:00The changing epidemiology and treatment of glomerular diseases – Michał Nowicki
13:00-14:30Session 1 – IgA Nephropathy: the evolving landscape
13:00-13:30 How do we optimize standard of care? – Izabela Zakrocka
13:30-14:00Progress in IgAN: the approval status of drugs with positive Phase 3 results – Şafak Mirioğlu
14:00-14:30The future of therapies in IgAN – Chee Kay Cheung
14:30-15:00Coffee Break
15:00-16:30Session 2 – ANCA-associated vasculitis
15:00-15:30 Complement inhibition in AAV – Annette Bruchfeld
15:30-16:00 Kidney risk scores: how did they evolve and how to implement them? – Ingeborg Bajema
16:00-16:30The future of AAV therapies – Sarah Moran
16:30-18:00Session 3 – Membranous nephropathy
16:30-17:00Why do we need new endpoints in MN trials? (virtual) – Tobias B. Huber
17:00-17:30Is rituximab the solution for all patients with MN? – Anna Matyjek
17:30-18:00Trial landscape and outlook – Andreas Kronbichler
09:00-10:30Session 4 – Lupus Nephritis
09:00-09:30The pathophysiology of SLE and LN revisited – Eleni Frangou
09:30-10:00Current standard of care and its limitations – Luis F. Quintana
10:00-10:30The future of lupus nephritis therapy – Onno Y. K. Teng
  
10:30-12:00Session 5 – Overlooked and understudied
10:30-11:00Sex dimorphism in kidney health and disease – Stefanie Steiger
11:00-11:30Sex representation of glomerular diseases – observational studies and trials – Kate I. Stevens
11:30-12:00Challenges in the management of glomerular diseases in resource-limited settings – Ewa Pawlowicz-Szlarska
12:00-13:00Lunch